RxDoctor Payments Data

Gina Winnette, APRN

Family · Statesboro, GANPI 1417274358

Payments from drug & device makers

$3,623in general payments, 2019–2025

Across 175 payments — averaging $20.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$1K
  • Viiv Healthcare Company$1K
  • Johnson & Johnson$568
  • Merck$261
  • Janssen Products, LP$99
  • EMD Serono, Inc.$40
  • plus $29 from 1 others

What the payments were for

  • Food & beverage$3,48596%
  • Education$1384%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,623 in reported general payments places this provider in the 85th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$3,932
Medicare patients
26
Services billed
62

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala207$818,930
JulucaDolutegravir/Rilpivirine87$298,913
DovatoDolutegravir Sodium/Lamivudine80$235,906
GenvoyaElviteg/Cob/Emtri/Tenof Alafen43$170,808
StribildElviteg/Cob/Emtri/Tenofo Disop28$110,808
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf22$104,048
TivicayDolutegravir Sodium27$75,709
OdefseyEmtricitab/Rilpiviri/Tenof Ala13$46,160
EdurantRilpivirine Hcl16$24,716
Darunavir15$22,198
Emtricitabine13$2,100
Lamivudine HbvLamivudine17$1,983
Abacavir-LamivudineAbacavir Sulfate/Lamivudine16$1,929
Megestrol Acetate11$1,598
Ritonavir19$1,380

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Stribild$1,485$1,100,545278 claims
Viiv Healthcare CompanyJuluca, Dovato, Tivicay$1,141$610,528194 claims
Janssen Products, LPSymtuza$99$104,04822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,258 family providers in Georgia.

Other family in Statesboro

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →